参考文献/References:
[1].Polimeni A. Coronary Artery Disease[J]. Cardiol Clin,2020,38(4):i.
[2].Picard F,Doucet S,Asgar AW. Contemporary use of drug-coated balloons in coronary artery disease:Where are we now?[J]. Arch Cardiovasc Dis,2017,110(4):259-272.
[3].Erdogan E,Bajaj R,Lansky A,et al. Intravascular Imaging for Guiding In-Stent Restenosis and Stent Thrombosis Therapy[J]. J Am Heart Assoc,2022,11(22):e026492.
[4].Li M,Hou J,Gu X,et al. Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China[J]. Eur J Med Res,2022,27(1):12.
[5].Schmidt K,Kraft HG,Parson W,et al. Genetics of the Lp(a)/apo(a) system in an autochthonous Black African population from the Gabon[J]. Eur J Hum Genet,2006,14(2):190-201.
[6].Nakano M,Otsuka F,Yahagi K,et al. Human autopsy study of drug-eluting stents restenosis:histomorphological predictors and neointimal characteristics[J]. Eur Heart J,2013,34(42):3304-3313.
[7].Kim BG,Kachel M,Kim JS,et al. Clinical implications of poststent optical coherence tomographic findings:severe malapposition and cardiac events[J]. JACC Cardiovasc Imaging,2022,15(1):126-137.
[8].Kronenberg F. Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region[J]. Clin Res Cardiol Suppl,2019,14(Suppl 1):5-12.
[9].Scheller B,Mangner N,Abdul Kader MASK,et al. Combined analysis of two parallel randomized trials of sirolimus-coated and paclitaxel-coated balloons in coronary in-stent restenosis lesions[J]. Circ Cardiovasc Interv,2022,15(9):e012305.
[10].Anglés-Cano E,Hervio L,Rouy D,et al. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator[J]. Chem Phys Lipids,1994,67-68:369-380.
[11].Caplice NM,Panetta C,Peterson TE,et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor:a novel link between lipoproteins and thrombosis[J]. Blood,2001,98(10):2980-2987.
[12].Romagnuolo R,Marcovina SM,Boffa MB,et al. Inhibition of plasminogen activation by apo(a):role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a)[J]. J Lipid Res,2014,55(4):625-634.
[13].Khan TZ,Gorog DA,Arachchillage DJ,et al. Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a):Findings from a randomized controlled cross-over trial[J]. J Clin Lipidol,2019,13(5):788-796.
[14].Gach O,Biémar C,Nys M,et al. Early release of neutrophil markers of activation after direct stenting in patients with unstable angina[J]. Coron Artery Dis,2005,16(1):59-65.
[15].Schnitzler JG,Hoogeveen RM,Ali L,et al. Atherogenic lipoprotein(a) increases vascular glycolysis,thereby facilitating inflammation and leukocyte extravasation[J]. Circ Res,2020,126(10):1346-1359.
[16].Orsó E,Schmitz G. Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies[J]. Clin Res Cardiol Suppl,2017,12(Suppl 1):31-37.
[17].Langsted A,Kamstrup PR,Nordestgaard BG. Lipoprotein(a):fasting and nonfasting levels,inflammation,and cardiovascular risk[J]. Atherosclerosis,2014,234(1):95-101.
[18].van der Valk FM,Bekkering S,Kroon J,et al. Oxidized Phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans[J]. Circulation,2016,134(8):611-624.
[19].Zhang M,Cresswell N,Tavora F,et al. In-stent restenosis is associated with neointimal angiogenesis and macrophage infiltrates[J]. Pathol Res Pract,2014,210(12):1026-1030.
[20].Kiechl S,Willeit J. The mysteries of lipoprotein(a) and cardiovascular disease revisited[J]. J Am Coll Cardiol,2010,55(19):2168-2170.
[21].Ryan MJ,Emig LL,Hicks GW,et al. Localization of lipoprotein(a) in a monkey model of rapid neointimal growth[J]. Arterioscler Thromb Vasc Biol,1997,17(1):181-187.
[22].Nakaya Y,Fukuda D,Oyamada T,et al. A novel lipoprotein (a) lowering drug,D-47,decreases neointima thickening after vascular injury[J]. J Med Invest,2017,64(1.2):64-67.
[23].Kamitani T,Taniguchi T,Miyai N,et al. Association between plasma lipoprotein(a) concentration and restenosis after stent implantation[J]. Circ J,2005,69(6):644-649.
[24].黎洁雯,龙洁旎,李明星,等.脂蛋白(a)水平对冠心病患者药物洗脱支架置入术后支架内再狭窄及非靶病变的影响[J].解放军医学杂志,2019,44(10):851-856.
[25].Yuan X,Han Y,Hu X,et al. Lipoprotein (a) is related to In-Stent neoatherosclerosis incidence rate and plaque vulnerability:Optical Coherence Tomography Study[J]. Int J Cardiovasc Imaging,2023,39(2):275-284.
[26].Otsuka F,Byrne RA,Yahagi K,et al. Neoatherosclerosis:overview of histopathologic findings and implications for intravascular imaging assessment[J]. Eur Heart J,2015,36(32):2147-2159.
[27].Tsimikas S,Gordts PLSM,Nora C,et al. Statin therapy increases lipoprotein(a) levels[J]. Eur Heart J,2020,41(24):2275-2284.
[28].Parish S,Hopewell JC,Hill MR,et al. Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE study[J]. Circ Genom Precis Med,2018,11(2):e001696.
[29].Blom DJ,Raal FJ,Santos RD,et al. Lomitapide and mipomersen-inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 synthesis[J]. Curr Atheroscler Rep,2019,21(12):48.
[30].O’Donoghue ML,Fazio S,Giugliano RP,et al. Lipoprotein(a),PCSK9 inhibition,and cardiovascular risk[J]. Circulation,2019,139(12):1483-1492.
[31].Roeseler E,Julius U,Heigl F,et al. Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease:prospective 5 years of follow-up and apolipoprotein(a) characterization[J]. Arterioscler Thromb Vasc Biol,2016,36(9):2019-2027.
[32].[32]Tsimikas S,Karwatowska-Prokopczuk E,Gouni-Berthold I,et al. Lipoprotein(a) reduction in persons with cardiovascular disease[J]. N Engl J Med,2020,382(3):244-255.
相似文献/References:
[1]赵丹 周鹏.达比加群及其逆转剂在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):801.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.034]
ZHAO DanZHOU Peng.Dabigatran and Reversal in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(9):801.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.034]
[2]陈元 楚天舒 武力勇.瘦素抵抗、瘦素受体基因多态性与冠状动脉粥样硬化性心脏病的相关性进展[J].心血管病学进展,2019,(8):1130.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.015]
CHEN Yuan,CHU Tianshu,WU Liyong.Leptin Resistance,Leptin Receptor Gene Polymorphism and Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(9):1130.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.015]
[3]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[4]孙涛 左权 周辉 刘安康 梁诚 汤圣兴.末梢桡动脉和无鞘技术在冠状动脉介入治疗中的应用现状[J].心血管病学进展,2020,(5):456.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.005]
[5]奚云萍 臧雁翔 李为民.临床SYNTAX计分及其衍生计分在冠心病血运重建预后中的应用价值[J].心血管病学进展,2020,(5):452.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.004]
XI Yunping,ZANG Yanxiang,LI Weimin.Value of Clinical SYNTAX Score and Its Derivative Score in Prognosis of Coronary Artery Disease with Revascularization[J].Advances in Cardiovascular Diseases,2020,(9):452.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.004]
[6]肖亚楠 高传玉 朱中玉.低剂量替格瑞洛在冠心病中的应用前景[J].心血管病学进展,2020,(7):706.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.009]
XIAO Yanan,GAO Chuanyu,ZHU Zhongyu.Application Prospects of Low-dose Ticagrelor in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(9):706.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.009]
[7]史云聪,王立立 郭艺芳.维生素D与心血管疾病相关性研究进展[J].心血管病学进展,2020,(8):826.[doi:10.16806/j.cnki.issn.1004-3934.20.08.011]
SHI YuncongWANG LiliGUO Yifang.Vitamin D And Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(9):826.[doi:10.16806/j.cnki.issn.1004-3934.20.08.011]
[8]李英 刘兴鹏.常见心血管病服药依从性[J].心血管病学进展,2020,(10):1016.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.000]
LI Ying,LIU Xingpeng.Medication Adherence For Common Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2020,(9):1016.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.000]
[9]肖亚楠 高传玉.经皮冠脉介入术后短程双联抗血小板治疗的研究进展[J].心血管病学进展,2021,(4):318.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.008]
XIAO Yanan,GAO Chuanyu.Short-term Dual Antiplatelet Therapy after Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2021,(9):318.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.008]
[10]吉蓉 寿锡凌.秋水仙碱在冠状动脉粥样硬化性心脏病防治中的研究进展与争议[J].心血管病学进展,2022,(1):60.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.016]
JI Rong,SHOU Xiling.Research Progress and Controversy of Colchicine in Prevention and Treatment of Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2022,(9):60.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.016]